Urologists examine the role of robotics, equality, exercise and medicine in bladder cancer

NEW ORLEANSMay 14, 2022 /PRNewswire/ — Do socioeconomic differences affect the care of a patient with bladder cancer? Can exercise improve the health of bladder cancer patients during treatment? What technological and pharmacological advances do urologists use to treat bladder cancer?

Researchers will present these bladder cancer research findings at the 117e Annual Scientific Meeting of the American Urological Association (AUA). Benjamin DaviesMD, professor of urology at the University of Pittsburgh School of Medicine and director of the Urologic Oncology Program at the Shadyside/Hillman Cancer Center, will moderate a press session featuring the following four abstracts at the Ernest N. Morial Convention Center in New Orleans On May 14, 2022Bee 11 a.m. CT

Boris GershmanMD, at Beth Israel Deaconess Medical Center, examined socioeconomic inequalities and their potential impact on the treatment of non-muscle invasive bladder cancer (NMIBC) despite strong clinical practice guidelines. “Differences in the Prevalence and Management of High-Risk Non-Muscle-Invasive Bladder Cancer”

Not much is known about the impact of a patient’s behavioral habits on bladder cancer, so Mara KoelkerMD, at Brigham and Women’s Hospital, examined the role of exercise on self-reported physical health status. “Impact of exercise on physical health status in bladder cancer patients”

Pramit KhetrapalMD, at University College London, examined the use of intracorporeal robot-assisted RC (iRAC) versus open RC (ORC) and its impact on the recovery time of a bladder cancer patient. “Results of the Intracorporeal Robotic vs Open Cystectomy (iROC) Multi-Centre Randomized Trial”

Disease-free survival was significantly improved with adjuvant nivolumab vs. placebo in patients with high-risk muscle-invasive urothelial carcinoma (MIUC) after radical surgery, according to Icahn School of Medicine at Mount Sinai’s Matthew GalskyMD† “Disease-free survival with extended follow-up of the CheckMate 274 trial of adjuvant nivolumab in patients after surgery for high-risk muscle-invasive urothelial carcinoma”

“The bladder cancer session highlights technological and pharmacological advances in bladder cancer care, as well as important work in equality and exercise,” said Dr. davies.

About the American Urological Association: The 117e Annual Meeting of the American Urological Association takes place May 13-16 at the Ernest N. Morial Convention Center in New Orleans† Founded in 1902 and headquartered near Baltimore, Maryland, the American Urological Association is a leading advocate of the specialty of urology and has nearly 24,000 members worldwide. The AUA is a premier urology association that provides invaluable support to the urology community in pursuing its mission to promote the highest standards of urologic care through education, research, and health policy formulation.

Media contact:
Caitlin LukacsManager Business Communication and Media Relations
410-689-4081, [email protected]

SOURCE American Urological Society

Leave a Comment